Changing the therapeutic landscape for patients with refractory metastatic colorectal cancer: FRESCO-2 supports fruquintinib as a global treatment option

by VHIO

The FRESCO-2 study has evaluated the efficacy and safety of fruquintinib in this patient population versus placebo. In patients treated with the new drug, the risk of disease progression in this refra...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Telum Therapeutics Secures €18 Million...

by Telum Therapeutics

Telum Therapeutics, a biotechnology company leveraging proprietary met...

Photos Stream